QL1706 Plus Lenvatinib
Phase 2Small molecule
Qilu Pharmaceutical Co., Ltd.QL1706 Plus Lenvatinib is one of 30 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
251 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QL1706 Plus Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details